DESCRIPTION
This series of interactive online modules presents foundational content on genomics followed by disease-specific activities covering major hematologic malignancies and relevant premalignant conditions. The GENOM Foundations modules starts by exploring the basics of genomics in the context of hematologic malignancies. Each Foundations module —On Target, The Toolbox, Clinical Applications, Patient Points, and On the Horizon — provides an introduction that is mirrored in the case-based Applications modules. The Applications modules are disease-specific interactive cases that cover ALL, AML and MDS, CLL, Lymphoma, and Myeloma. Learn the Foundations of genomics and then practice the skills in case Applications.

TARGET AUDIENCE
This activity is intended for hematologists, hematologists/oncologists, medical oncologists, nurses, physician assistants, and nurse practitioners caring for patients with blood cancers.

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Identify genomic principles, applications, technologies, and terminology relating to biomarker development
• Outline available tests available for treatment of hematologic malignancies
• Interpret test results and select appropriate management strategies
• Articulate strategies to explain tests and their implications to patients and caregivers
• Discuss ongoing genomics and genetics research in hematologic malignancies

STEERING COMMITTEE
Jennifer Brown, MD, PhD (Steering Committee Chair and Activity Faculty)
Director, CLL Center of the Division of Hematologic Malignancies
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Anjali Advani, MD
Director, Inpatient Leukemia Unit
Taussig Cancer Institute
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Data Safety and Monitoring Committee
Case Comprehensive Cancer Center
Cleveland, Ohio

Rafael Fonseca, MD
Director, Mayo Clinic Comprehensive Cancer Center
Director for Innovation and Transformational Relationships
Getz Family Professor of Cancer, Distinguished Mayo Investigator
Phoenix, Arizona

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC
Associate Professor and Program Director
Marcella Niehoff School of Nursing
Loyola University Chicago
Health Sciences Campus
Maywood, Illinois

Neha Mehta-Shah, MD, MSCI
Assistant Professor, Department of Medicine
Division of Medical Oncology
Washington University in St. Louis School of Medicine
St. Louis, Missouri

Alice Mims, MD
Acute Leukemia Clinical Research Director
Assistant Professor, Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Charles Mullighan, MBBS (Hons), MSc, MD
Deputy Director, Comprehensive Cancer Center
Co-Leader, Hematological Malignancies Program
Medical Director, St. Jude Biorepository
William E. Evans Endowed Chair
St. Jude Children’s Research Hospital
Memphis, Tennessee

MOC REVIEWERS
Chancellor Donald, MD
Tulane University
Assistant Professor of Medicine Hematology & Medical Oncology
UMCNO Cancer Management Medical Director

Judith Kleinerman, MD (retired)
Hematologist formerly at Medical Specialists of Taunton

APPLICATIONS CONTRIBUTING FACULTY
Daniel J. DeAngelo, MD, PhD
Chief, Division on Leukemia
Dana Farber Cancer Institute
Professor of Medicine
Harvard Medical School

Jeffery M. Klco, MD, PhD
Associate Member, Department of Pathology
Director, Division of Hematopathology and Molecular Pathology
St. Jude Children’s Research Hospital

David Kurtz, MD, PhD
Instructor
Division of Oncology, Department of Medicine
Stanford University Medical Center

Elizabeth A. Raetz, MD
KiDS of NYU Foundation Professor of Pediatrics
NYU School of Medicine
Director, Division of Pediatric Hematology/Oncology
Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders

Saad Z. Usmani, MD, MBA, FACP
Chief, Plasma Cell Disorders Program
Director, Clinical Research in Hematologic Malignancies
Clinical Professor of Medicine
Levine Cancer Institute/Atrium Health

Jennifer A. Woyach, MD
Associate Professor of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

MOC REVIEWERS
Chancellor Donald, MD
Tulane University
Assistant Professor of Medicine Hematology & Medical Oncology
UMCNO Cancer Management Medical Director

Judith Kleinerman, MD (retired)
Hematologist formerly at Medical Specialists of Taunton

ACCREDITED PROVIDER
This activity is provided by the American Society of Hematology and The Leukemia and Lymphoma Society in collaboration with The France Foundation.

TARGET AUDIENCE
This activity is intended for hematologists, hematologists/oncologists, medical oncologists, nurses, physician assistants and nurse practitioners caring for patients with blood cancers.

STATEMENT OF NEED
Genomic profiling is widely recognized as a key way to identify strategies for treating hematologic (and other) cancers. However, there is a significant disconnect between scientific evidence and hematologist/oncologist knowledge, confidence, and practice. As a wealth of new information continues to emerge, it is essential that hematologists/oncologists have a strong foundational understanding of genomics and its practical applications.

ACCREDITATION STATEMENT
The American Society of Hematology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award continuing education contact hours through the California Board of Registered Nursing.

CREDIT DESIGNATION
Physicians: The American Society of Hematology (ASH) designates each enduring activity for a maximum of 0.5 to 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses: Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing. Nurses must complete a minimum of 1 hour of learning. This course provides .5 hours. Nurses will be able to complete the evaluation and earn a certificate after they have completed enough courses to accumulate 1.0 or more hours.

DISCLOSURE POLICY
The France Foundation participated in the development of this activity in collaboration with the American Society of Hematology and The Leukemia and Lymphoma Society. In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF), the American Society of Hematology (ASH), and The Leukemia and Lymphoma Society (LLS) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF, ASH, and LLS resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF, ASH, and LLS seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF, ASH, and LLS are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures

The following staff at TFF report that they have relevant financial relationships to disclose:

• Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc and they hold stock in Pfizer, Inc.

All other planners, reviewers, editors, staff, CME committee, or other members at TFF who control content have no relevant financial relationships to disclose.

The planners, reviewers, editors, staff, CME committee, or other members at ASH and LLS who control content have no relevant financial relationships to disclose.

Faculty Disclosures–Steering Committee

The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Patricia Friend
• Dr. Alice Mims

The faculty listed below report that they have relevant financial relationships to disclose:

• Dr. Anjali Advani serves as a consultant for Amgen, Glycomimetics, Kite Pharmaceuticals, and Seattle Genetics. She does contract research for Abbvie, Macrogenics, Glycomimetics, and Pfizer, Inc. Dr. Advani also receives royalty payments from Pfizer, Inc.
• Dr. Jennifer Brown does consulting for Abbvie, Acerta/AstraZeneca, Beigene, Catapult, Dynamo Therapeutics, Juno/Celgene, MEI Pharma, Novartis, Nextcea, Octapharma, Pfizer, and Verastem. She also does contract research for Abbvie, Acerta/ AstraZeneca, Beigene, Gilead, Janssen, Loxo/Lilly, Pharmacyclics, Regeneron, Sun, and Verastem. Dr. Brown is also a member of the Data Safety Monitoring Committee for Invectys.
• Dr. Rafael Fonseca does consulting for Amgen, Bayer, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. He does contract research for Sanofi and owns stock in Adaptive Technologies. Dr. Fonseca holds a patent for using FISH for myeloma prognosis and receives royalties.
• Dr. Neha Mehta-Shah does consulting for C4 Therapeutics and Kiowa Hakka Kirin. She does contract research for Bristol-Myers Squibb, Celgene, and Verastem Pharmaceuticals.
• Dr. Charles Mullighan does consulting and serves on the speakers bureau for Amgen. He does contract research for Abbvie, Loxo Oncology, and Pfizer, Inc.

Faculty Disclosures-Applications Contributing Faculty

The faculty listed below report that they have no relevant financial relationships to disclose:

• • Dr. Jeffery Klco

The faculty listed below report that they have relevant financial relationships to disclose:

• Dr. Daniel DeAngelo serves as a consultant for Agios, Amgen, Autolos, Blueprint, Forty Seven, and Incyte. He does contract research for Abbvie, Blueprint, Glycomimetics, and Novartis.
• Dr. David Kurtz serves as a consultant for Roche.
• Dr. Elizabeth Raetz receives institutional research funding from Pfizer, and is a member of the DSMB for Celgene.
• Dr. Saad Usmani serves as a consultant for Amgen, Bristol-Myers Squibb, Celgene, EdoPharma, GlaxoSmithKline, Janssen, Merck, Sanofi, SkylineDx, and Takeda. He serves on the speakers bureau for Amgen, Celgene, Janssen, Sanofi, and Takeda. Dr. Usmani also does contract research for Amgen, Array Biopharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, and Takeda.
• Dr. Jennifer Woyach serves as a consultant for Arqule, AstraZeneca, Janssen, and Pharmacyclics. She also does contract research for Abbvie and Loxo.

MOC Reviewers Disclosures

The faculty listed below report that they have no relevant financial relationships to disclose:

• Dr. Judith Kleinerman

The faculty listed below report that they have relevant financial relationships to disclose:

• Dr. Chancellor Donald serves as a consultant and is a member of the Board of Advisory Committee for Pfizer, Inc.

DISCLOSURE OF UNLABELED USE
TFF, ASH, and LLS require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF, ASH, and LLS do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grants from Agios Pharmaceuticals, Inc; Astellas Pharma Inc.; Bristol Myers Squibb Company; Foundation Medicine, Inc.; Illumina, Inc.; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Servier Pharmaceuticals; and Verastem Oncology.

DISCLAIMER
The France Foundation, the American Society of Hematology, and The Leukemia and Lymphoma Society present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. TFF, ASH, LLS, and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2020 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy .

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.